{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-011066","form_type":"8-K","ticker":"PALI","cik":"0001357459","company_name":"PALISADE BIO, INC.","filed_at":"2023-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.550285+00:00","generated_at":"2026-06-17T05:44:38.938132+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Palisade Bio raises $6M in registered direct offering and private placement at $2.64/share","bullets":["Gross proceeds of ~$6.0M from sale of 2,272,723 shares/pre-funded warrants at $2.64 per share.","Includes 756,317 registered shares, unregistered shares/pre-funded warrants, and 2,272,723 common warrants (exercise $2.64, 5-year term).","Ladenburg Thalmann acted as placement agent; net proceeds for working capital and general corporate purposes.","Offering closed on April 5, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-011066","json":"https://secwatch.observer/filing/0001493152-23-011066.json","markdown":"https://secwatch.observer/filing/0001493152-23-011066.md","text":"https://secwatch.observer/filing/0001493152-23-011066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223011066/0001493152-23-011066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223011066/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T05:44:38.938132+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6f4c43f204c592d971b01c5ae19d749589936433","claim":"PALISADE BIO, INC. entered into Purchase Agreements with certain institutional and accredited investors valued at aggregate gross proceeds to the Company of approximately $6.0 million (effective 2023-04-03).","evidence_excerpt":"On April 3, 2023, Palisade Bio, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional and accredited investors (the “Purchasers”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223011066/0001493152-23-011066-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and accredited investors"},{"label":"Value","value":"aggregate gross proceeds to the Company of approximately $6.0 million"},{"label":"Effective","value":"2023-04-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}